The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The long term effects of GH replacement in adult GH-deficient (GHD) patients have not yet been clarified.

After completion of that trial, 10 patients received continuous GH replacement for the subsequent 10 yr, whereas 11 did not.

Who Took Part

The abstract describes 21 adults taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Some adults received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

PubMed files the paper under topics including Blood Pressure, Body Composition, Growth Hormone and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 21 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1999 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.